Progress of SGLT2 Inhibitors in the Treatment of Common Immune-related Nephropathies

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2024 Jul 4

PMID 38963512

Authors

Guoqian Hu

Yifan Wu

Feng Chen

Jin Tang

Affiliations

Soon will be listed here.

Abstract

The immune system can lead to a variety of renal diseases through direct or indirect mechanisms. In immune-mediated nephropathy, though standardized treatment, there are still a small number of patients with further decline in renal function, which may even progress to renal failure; sodium-glucose cotransporter protein 2 (SLC5A2,SGLT2) inhibitors not only can significantly reduce blood glucose, but also have an additional protective effect on the kidneys and the heart; this review concludes the potential mechanism of the renal protective effect of SGLT2i and the new advances in the recent years in common immune-mediated nephropathies, which can provide new theoretical references to optimize the therapeutic strategy of common immune-mediated nephropathies.

References

Kant S, Kronbichler A, Sharma P, Geetha D . Advances in Understanding of Pathogenesis and Treatment of Immune-Mediated Kidney Disease: A Review. Am J Kidney Dis. 2021; 79(4):582-600. DOI: 10.1053/j.ajkd.2021.07.019. View

Kurts C, Panzer U, Anders H, Rees A . The immune system and kidney disease: basic concepts and clinical implications. Nat Rev Immunol. 2013; 13(10):738-53. DOI: 10.1038/nri3523. View

Kaminski H, Couzi L, Eberl M . Unconventional T cells and kidney disease. Nat Rev Nephrol. 2021; 17(12):795-813. DOI: 10.1038/s41581-021-00466-8. View

Cowie M, Fisher M . SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020; 17(12):761-772. DOI: 10.1038/s41569-020-0406-8. View

Khemais-Benkhiat S, Belcastro E, Idris-Khodja N, Park S, Amoura L, Abbas M . Angiotensin II-induced redox-sensitive SGLT1 and 2 expression promotes high glucose-induced endothelial cell senescence. J Cell Mol Med. 2019; 24(3):2109-2122. PMC: 7011151. DOI: 10.1111/jcmm.14233. View

El-Daly M, Venu V, Saifeddine M, Mihara K, Kang S, Fedak P . Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress. Vascul Pharmacol. 2018; 109:56-71. DOI: 10.1016/j.vph.2018.06.006. View

Miyata K, Zhang S, Chan J . The Rationale and Evidence for SGLT2 Inhibitors as a Treatment for Nondiabetic Glomerular Disease. Glomerular Dis. 2023; 1(1):21-33. PMC: 9677741. DOI: 10.1159/000513659. View

Hakroush S, Tampe D, Kluge I, Baier E, Korsten P, Tampe B . Comparative analysis of SGLT-2 expression in renal vasculitis and lupus nephritis. Ann Rheum Dis. 2022; 81(7):1048-1050. PMC: 9209668. DOI: 10.1136/annrheumdis-2022-222167. View

Guo R, Wang P, Zheng X, Cui W, Shang J, Zhao Z . SGLT2 inhibitors suppress epithelial-mesenchymal transition in podocytes under diabetic conditions downregulating the IGF1R/PI3K pathway. Front Pharmacol. 2022; 13:897167. PMC: 9550168. DOI: 10.3389/fphar.2022.897167. View

10.

Huang F, Zhao Y, Wang Q, Hillebrands J, van den Born J, Ji L . Dapagliflozin Attenuates Renal Tubulointerstitial Fibrosis Associated With Type 1 Diabetes by Regulating STAT1/TGFβ1 Signaling. Front Endocrinol (Lausanne). 2019; 10:441. PMC: 6616082. DOI: 10.3389/fendo.2019.00441. View

11.

Li D, Yu K, Feng F, Zhang Y, Bai F, Zhang Y . Hydroxychloroquine alleviates renal interstitial fibrosis by inhibiting the PI3K/Akt signaling pathway. Biochem Biophys Res Commun. 2022; 610:154-161. DOI: 10.1016/j.bbrc.2022.04.058. View

12.

Vanarsa K, Soomro S, Zhang T, Strachan B, Pedroza C, Nidhi M . Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis. Ann Rheum Dis. 2020; 79(10):1349-1361. PMC: 7839323. DOI: 10.1136/annrheumdis-2019-216312. View

13.

Chalkia A, Gakiopoulou H, Theochari I, Foukas P, Vassilopoulos D, Petras D . TGF-β1/Smad Signalling in Proliferative Glomerulonephritis Associated with Autoimmune Diseases. Mediterr J Rheumatol. 2022; 33(2):176-184. PMC: 9450207. DOI: 10.31138/mjr.33.2.176. View

14.

Khalili M, Bonnefoy A, Genest D, Quadri J, Rioux J, Troyanov S . Clinical Use of Complement, Inflammation, and Fibrosis Biomarkers in Autoimmune Glomerulonephritis. Kidney Int Rep. 2020; 5(10):1690-1699. PMC: 7569694. DOI: 10.1016/j.ekir.2020.07.018. View

15.

Lai Z, Borsuk R, Shadakshari A, Yu J, Dawood M, Garcia R . Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus. J Immunol. 2013; 191(5):2236-46. PMC: 3777662. DOI: 10.4049/jimmunol.1301005. View

16.

Wu C, Fu Q, Guo Q, Chen S, Goswami S, Sun S . Lupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated. Ann Rheum Dis. 2019; 78(8):1090-1100. PMC: 6691860. DOI: 10.1136/annrheumdis-2019-215039. View

17.

Zhao X, Li S, He Y, Yan L, Lv F, Liang Q . SGLT2 inhibitors alleviated podocyte damage in lupus nephritis by decreasing inflammation and enhancing autophagy. Ann Rheum Dis. 2023; 82(10):1328-1340. DOI: 10.1136/ard-2023-224242. View

19.

Abdollahi E, Keyhanfar F, Delbandi A, Falak R, Hajimiresmaiel S, Shafiei M . Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-κB activation in human endothelial cells and differentiated macrophages. Eur J Pharmacol. 2022; 918:174715. DOI: 10.1016/j.ejphar.2021.174715. View

20.

Lee N, Heo Y, Choi S, Jeon J, Han S, Kim D . Anti-inflammatory Effects of Empagliflozin and Gemigliptin on LPS-Stimulated Macrophage via the IKK/NF-B, MKK7/JNK, and JAK2/STAT1 Signalling Pathways. J Immunol Res. 2021; 2021:9944880. PMC: 8192181. DOI: 10.1155/2021/9944880. View

21.

Lu Y, Wu H, Zhu T, Li X, Zuo J, Hasan A . Empagliflozin reduces kidney fibrosis and improves kidney function by alternative macrophage activation in rats with 5/6-nephrectomy. Biomed Pharmacother. 2022; 156:113947. DOI: 10.1016/j.biopha.2022.113947. View